Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Empirical Finance LLC

Empirical Finance LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.0% in the third quarter, Holdings Channel.com reports. The firm owned 8,613 shares of the company’s stock after acquiring an additional 334 shares during the period. Empirical Finance LLC’s holdings in Moderna were worth $576,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Commerzbank Aktiengesellschaft FI lifted its stake in shares of Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after acquiring an additional 93 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC grew its position in shares of Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares in the last quarter. McAdam LLC increased its stake in shares of Moderna by 1.1% in the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after buying an additional 117 shares during the last quarter. Finally, 180 Wealth Advisors LLC raised its holdings in Moderna by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock valued at $1,826,000 after acquiring an additional 160 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 2,930 shares of company stock worth $217,170 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on MRNA shares. Piper Sandler decreased their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Jefferies Financial Group lowered their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. JPMorgan Chase & Co. reduced their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday, November 4th. Leerink Partners lowered their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Finally, Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $90.22.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $36.85 on Monday. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69. The stock has a 50 day simple moving average of $58.56 and a 200-day simple moving average of $96.78.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.39) EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.43 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.